Inventory decreased 24.1%
Inventory changed -24.1% from the comparable as-filed period.
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Inventory changed -24.1% from the comparable as-filed period.
Free-cash-flow margin changed -8234 basis points from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Operating cash-flow margin changed -8194 basis points from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
R&D / revenue changed +2872 basis points from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Receivables / revenue changed -373 basis points from the comparable as-filed period.
Research & development changed -9.0% from the comparable as-filed period.
Capex / revenue changed +40 basis points from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Current ratio changed -9.7% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Capital expenditure changed +0.0% from the comparable as-filed period. Relative percentage is de-emphasized because the comparison has a zero base.
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.